- Home
- / Aptevo Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Aptevo Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.3
2024-10-29
Market Capitalization
$4.1 M
2024-10-29
Revenue
$3.1 M
FY, 2022
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 36.4M | 14.7M | 23.1M | 32.4M | 4.3M | 12.3M | 3.1M | |||
| Revenue growth, % | -59.8% | 57.4% | ||||||||
| Cost of goods sold | 24.2M | 5.0M | 11.2M | 19.9M | ||||||
| Gross profit | 12.3M | 9.6M | 11.9M | 12.5M | ||||||
| Gross profit margin, % | 33.6% | 65.8% | 51.4% | 38.5% | ||||||
| General and administrative expense | 38.7M | 34.6M | 28.1M | 25.3M | 11.8M | 10.2M | ||||
| Operating expense total | 68.2M | 63.6M | 63.5M | 55.1M | 24.6M | |||||
| EBIT | (126.9M) | (53.9M) | (51.7M) | (42.6M) | (27.5M) | (21.4M) | (28.6M) | (28.9M) | (24.6M) | (26.3M) |
| EBIT margin, % | -348.4% | -368.1% | -224.0% | -131.4% | -638.1% | -919.7% | ||||
| Pre tax profit | (127.8M) | (55.9M) | (53.7M) | (44.7M) | (30.9M) | (29.4M) | 7.0M | (18.6M) | (24.1M) | (26.0M) |
| Income tax expense | (15.3M) | (23.3M) | ||||||||
| Net Income | (112.4M) | 7.0M | (53.7M) | (40.4M) | (17.7M) | (28.5M) | 8.0M | (17.4M) | (24.1M) | (26.0M) |
| EPS | 1.6 | (1.0) | (87.4) | (87.3) |